image credit: Freepik

Jazz Pharmaceuticals to acquire GW Pharma for $7.2bn

February 8, 2021

Jazz Pharmaceuticals has announced that it will acquire London-headquartered biopharma company GW Pharma for a total consideration of $7.2bn.

GW is focused on the discovery and development of therapeutics from its proprietary cannabinoid product platform.

The company’s lead product is Epidiolex (cannabidiol) oral solution, which is approved in patients aged one-year and older for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome and Tuberous Sclerosis Complex (TSC).

Read More on Pharma Times